Clinicians' guide to microarrays

L Maraqa, C F Donnellan, M B Peter, V Speirs

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Cancer is a heterogeneous disease with wide-ranging subsets of patients who have different prognoses and who respond differently to treatments. Accordingly, deciding the best treatment strategy has become a priority in cancer care. The development of microarray technology over the last decade has caused great excitement, with the promise that these new tools may provide molecular signatures to help predict patient outcome and direct therapeutic approaches. Here, we describe the different types of microarrays available and discuss their pros and cons from a clinical perspective, with respect to breast cancer.

Original languageEnglish
Pages (from-to)205-10
Number of pages6
JournalEuropean Journal of Surgical Oncology
Volume15
Issue number4
DOIs
Publication statusPublished - Dec 2006

Fingerprint

Neoplasms
Therapeutics
Breast Neoplasms
Technology

Keywords

  • Biomarkers, Tumor
  • Gene Expression
  • Humans
  • Neoplasms
  • Oligonucleotide Array Sequence Analysis
  • Prognosis
  • RNA, Neoplasm
  • Treatment Outcome
  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review

Cite this

Clinicians' guide to microarrays. / Maraqa, L; Donnellan, C F; Peter, M B; Speirs, V.

In: European Journal of Surgical Oncology, Vol. 15, No. 4, 12.2006, p. 205-10.

Research output: Contribution to journalReview article

Maraqa, L ; Donnellan, C F ; Peter, M B ; Speirs, V. / Clinicians' guide to microarrays. In: European Journal of Surgical Oncology. 2006 ; Vol. 15, No. 4. pp. 205-10.
@article{e9c9f7117c404596add2b9252ae142de,
title = "Clinicians' guide to microarrays",
abstract = "Cancer is a heterogeneous disease with wide-ranging subsets of patients who have different prognoses and who respond differently to treatments. Accordingly, deciding the best treatment strategy has become a priority in cancer care. The development of microarray technology over the last decade has caused great excitement, with the promise that these new tools may provide molecular signatures to help predict patient outcome and direct therapeutic approaches. Here, we describe the different types of microarrays available and discuss their pros and cons from a clinical perspective, with respect to breast cancer.",
keywords = "Biomarkers, Tumor, Gene Expression, Humans, Neoplasms, Oligonucleotide Array Sequence Analysis, Prognosis, RNA, Neoplasm, Treatment Outcome, Journal Article, Research Support, Non-U.S. Gov't, Review",
author = "L Maraqa and Donnellan, {C F} and Peter, {M B} and V Speirs",
year = "2006",
month = "12",
doi = "10.1016/j.suronc.2006.12.003",
language = "English",
volume = "15",
pages = "205--10",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Clinicians' guide to microarrays

AU - Maraqa, L

AU - Donnellan, C F

AU - Peter, M B

AU - Speirs, V

PY - 2006/12

Y1 - 2006/12

N2 - Cancer is a heterogeneous disease with wide-ranging subsets of patients who have different prognoses and who respond differently to treatments. Accordingly, deciding the best treatment strategy has become a priority in cancer care. The development of microarray technology over the last decade has caused great excitement, with the promise that these new tools may provide molecular signatures to help predict patient outcome and direct therapeutic approaches. Here, we describe the different types of microarrays available and discuss their pros and cons from a clinical perspective, with respect to breast cancer.

AB - Cancer is a heterogeneous disease with wide-ranging subsets of patients who have different prognoses and who respond differently to treatments. Accordingly, deciding the best treatment strategy has become a priority in cancer care. The development of microarray technology over the last decade has caused great excitement, with the promise that these new tools may provide molecular signatures to help predict patient outcome and direct therapeutic approaches. Here, we describe the different types of microarrays available and discuss their pros and cons from a clinical perspective, with respect to breast cancer.

KW - Biomarkers, Tumor

KW - Gene Expression

KW - Humans

KW - Neoplasms

KW - Oligonucleotide Array Sequence Analysis

KW - Prognosis

KW - RNA, Neoplasm

KW - Treatment Outcome

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

KW - Review

U2 - 10.1016/j.suronc.2006.12.003

DO - 10.1016/j.suronc.2006.12.003

M3 - Review article

C2 - 17291747

VL - 15

SP - 205

EP - 210

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 4

ER -